Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023 (Focus on Biomarker Test Type, Application & Market Trends)

  • ID: 4176294
  • Report
  • Region: Global
  • 341 pages
  • BIS Research
1 of 5
The Global Emerging Cancer Diagnostics Market Is Expected To Grow At A CAGR Of 13.45% From 2016 To 2023 And Reach A Figure Of $6.34 Billion By 2023

FEATURED COMPANIES

  • Abbott Laboratories, Inc
  • Becton Dickinson & Co
  • Cancer Genetics Inc
  • Ignyta,Inc
  • Luminex Corporation
  • Qiagen, Inc
  • MORE

Cancer is a chronic disease and is affecting a huge population. Many technologies are emerging in the cancer diagnostics market. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others.

This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report. All of the above mentioned report coverage parameters are discussed across different regions such as North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market.

The answers to the following key questions can be found in the report:

  •  What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases?
  •  How is the tumor biomarker test market evolving?
  •  What are the market shares of the leading segments of the tumor biomarker test market in 2015?
  •  How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023?
  •  How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023?
  •  How the industry will evolve during the forecast period between 2017 and 2023?
  •  What are the key developmental strategies implemented in different applications across all regions?
  •  How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others?
  •  Which geographical region will lead the global tumor biomarker test market by the end of the forecast period?
  •  Who are the key players in the tumor biomarker test market?
  •  What are different application in this market and how are they categorized?
  •  What are the market trends and key developments in different geographical regions?
  •  What are all market available cancer biomarker test?
  •  What is the current market size and future projection for emerging cancer technologies in the major countries?
  •  What are the key sources of information about emerging cancer technologies?
  •  What is the incidence rate of major cancer type?

The research study tries to answer various aspects of the emerging cancer diagnostics market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter’s Five Force model and opportunity matrix for an in-depth study of the emerging cancer diagnostics market and an assessment of the factors governing the same.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories, Inc
  • Becton Dickinson & Co
  • Cancer Genetics Inc
  • Ignyta,Inc
  • Luminex Corporation
  • Qiagen, Inc
  • MORE

Executive Summary

1 The Research Scope and Methodology
1.1 Scope of the Report
1.2 Global Emerging Cancer Diagnostics Market Research Methodology

2 Introduction to Global Emerging Cancer Diagnostics Market
2.1 Overview
2.2 Analysis of Lifestyle Factors
2.2.1 Obesity/Weight
2.2.2 Physical Activity
2.2.3 Food Habits
2.2.4 Alcohol & Cancer
2.2.4.1 Countries with Highest Consumption of Alcoholic Drinks
2.2.5 Salt Consumption
2.2.6 Breastfeeding
2.3 High and Low Developed Countries
2.3.1 Men
2.3.2 Women
2.4 Data for Cancer Frequency by Country
2.4.1 Men
2.4.2 Women
2.5 Worldwide Cancer Data
2.5.1 Men
2.5.2 Women

3 Market Dynamics
3.1 Market Drivers
3.1.1 Increase in Prevalence Rate of Cancer
3.1.2 Increase in Sedentary Lifestyles
3.1.3 Robust Technological Advancement
3.1.4 Environmental Hazards
3.1.4.1 Five Primary Categories of Carcinogens are: -
3.1.5 Government Initiatives and Investment
3.2 Market Challenges
3.2.1 High Capital Investment
3.2.2 Dearth of Skilled Professionals
3.2.3 Lack of Awareness
3.3 Market Opportunities
3.3.1 Nanotechnology Applications in Cancer
3.3.2 3D Printing in Cancer Diagnostics
3.3.3 Robotics in Cancer Diagnostics and Treatment
3.3.4 Fluid Biopsy
3.3.5 Real Time Cancer Diagnostic iKnife

4 Competitive Insights
4.1 Key Market Developments & Strategies
4.1.1 Product Launch and Development
4.1.2 Collaborations, Joint Ventures & Partnerships
4.1.3 Business Expansion and Contracts
4.1.4 Patents, Approvals and Certifications
4.1.5 Mergers and Acquisitions
4.1.6 Other Strategies
4.2 Industry Attractiveness
4.3 Global Market Share Analysis
4.3.1 Market Share Analysis

5 Industry Analysis
5.1 Patent Analysis
5.2 Consortiums, Associations and Regulatory Bodies

6 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast
6.1 Assumptions & Limitations for Analysis and Forecast
6.2 Market Overview
6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test
6.3.1 Prostate Specific Antigen Tests
6.3.2 CTC Tests
6.3.3 Alpha-Fetoprotein (AFP) Tests
6.3.4 CA Test
6.3.4.1 CA 19-9 Tests
6.3.4.2 CA 125 Tests
6.3.5 HER2 Tests
6.3.6 BRCA Test
6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests
6.3.8 EGFR Mutation Tests
6.3.9 KRAS Test
6.3.10 Others
6.3.10.1 National Rental Affordability Scheme (NRAS) Testing
6.3.10.2 RET Gene Testing
6.3.10.3 ROS Testing
6.3.10.4 PIK3CA Tests
6.4 Global Emerging Cancer Diagnostics Market by Application
6.4.1 Lung Cancer
6.4.2 Breast Cancer
6.4.3 Colorectal
6.4.4 Prostate Cancer
6.4.5 Blood Cancer
6.4.5.1 Leukaemia
6.4.5.2 Lymphoma
6.4.5.3 Myeloma
6.4.6 Others
6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography
6.5.1 North America
6.5.1.1 Country Analysis
6.5.1.1.1 U.S.
6.5.1.1.2 Canada
6.5.2 Europe
6.5.2.1 Countries Having the Highest Cancer Rates
6.5.2.2 Germany
6.5.2.3 France
6.5.2.4 The U.K.
6.5.2.5 Denmark
6.5.2.6 Belgium
6.5.2.7 Norway
6.5.3 APAC
6.5.3.1 India
6.5.3.2 China
6.5.3.3 Japan
6.5.3.4 Australia
6.5.3.5 Singapore
6.5.3.6 Others APAC Region
6.5.4 Rest of the World
6.5.4.1 Middle East
6.5.4.2 Africa
6.5.4.3 South America

7 Company Profiles
7.1 Abbott Laboratories, Inc.
7.1.1 Overview
7.1.2 Financials
7.1.2.1 Financial Summary
7.1.3 SWOT Analysis
7.2 Agilent Technologies
7.2.1 Overview
7.2.2 Financials
7.2.2.1 Financial Summary
7.2.3 SWOT Analysis
7.3 AstraZeneca
7.3.1 Overview
7.3.2 Financials
7.3.2.1 Financial Summary
7.3.3 SWOT Analysis
7.4 Becton Dickinson & Co.
7.4.1 Overview
7.4.2 Financials
7.4.2.1 Financial Summary
7.4.3 SWOT Analysis
7.5 Biocept Inc.
7.5.1 Overview
7.5.2 Financials
7.5.2.1 Financial Summary
7.5.3 SWOT Analysis
7.6 Cancer Genetics Inc.
7.6.1 Overview
7.6.2 Financials
7.6.2.1 Financial Summary
7.6.3 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Overview
7.7.2 Financials
7.7.2.1 Financial Summary
7.7.3 SWOT Analysis
7.8 Foundation Medicine Inc.
7.8.1 Overview
7.8.2 Financials
7.8.2.1 Financial Summary
7.8.3 SWOT Analysis
7.9 Illumina Inc.
7.9.1 Overview
7.9.2 Financials
7.9.2.1 Financial Summary
7.9.3 SWOT Analysis
7.10 LabCorp Of America Holdings
7.10.1 Overview
7.10.2 Financials
7.10.2.1 Financial Summary
7.10.3 SWOT Analysis
7.11 Luminex Corporation
7.11.1 Overview
7.11.2 Financials
7.11.2.1 Financial Summary
7.11.3 SWOT Analysis
7.12 Myriad Genetics Inc.
7.12.1 Overview
7.12.2 Financials
7.12.2.1 Financial Summary
7.12.3 SWOT Analysis
7.13 NanoString Technologies Inc.
7.13.1 Overview
7.13.2 Financials
7.13.2.1 Financial Summary
7.13.3 SWOT Analysis
7.14 Neo Genomics Inc.
7.14.1 Overview
7.14.2 Financials
7.14.2.1 Financial Summary
7.14.1 SWOT Analysis
7.15 Quest Diagnostics Incorporated
7.15.1 Overview
7.15.2 Financials
7.15.2.1 Financial Summary
7.15.3 SWOT Analysis
7.16 Qiagen, Inc.
7.16.1 Overview
7.16.2 Financials
7.16.2.1 Financial Summary
7.16.3 SWOT Analysis
7.17 Roche Holding AG-BR
7.17.1 Overview
7.17.2 Financials
7.17.2.1 Financial Summary
7.17.3 SWOT Analysis
7.18 Siemens Healthineers
7.18.1 Overview
7.18.2 Financials
7.18.2.1 Financial Summary
7.18.3 SWOT Analysis
7.19 Thermo Fisher Scientific
7.19.1 Overview
7.19.2 Financials
7.19.2.1 Financial Summary
7.19.3 SWOT Analysis
7.20 Snapshot of Other Key Players
7.20.1 Biotheranostics, Inc.
7.20.2 Epigenomics
7.20.3 Exact Sciences Corporation
7.20.4 Ignyta,Inc.
7.20.5 Interpace Diagnostics
7.20.6 Leica Biosystems
7.20.7 BioTime, Inc
7.20.8 Pathway Genomics
7.20.9 Sysmex Corporation
7.20.10 Almac group
7.20.11 GeneNews Limited (formerly ChondroGene Limited)
7.20.12 Rosetta Genomics

List of Tables

Table 2.1 Relation Between Obesity & Cancer
Table 2.2 Top 10 Countries with the Highest Percent (%) of Overweight or Obese Adults
Table 2.3 Top Countries with highest Consumption Alcohol in 201
Table 2.4 Top 20 Countries with Highest Consumption of Salt in 201
Table 2.5 Age-Standardised Rate per 100,000 (World)
Table 2.6 Age-Standardized Rate per 100,000 (World)
Table 2.7 Age-Standardised Rate per 100,000 (World)
Table 2.8 Cancer Rate Worldwide in Major Countries
Table 2.9 Cancer Rate in Men
Table 2.10 Cancer Rate in Women
Table 2.11 Worldwide Top Cancer Type Data
Table 2.12 Statistics of Top Cancer Types in Men
Table 2.13 Statistics of Top Cancer Types in Women
Table 2.14 Incidence of Major Type of Cancer
Table 2.15 Incidence of Cancer in Major Countries
Table 4.1 Product Launch and Development
Table 4.2 Collaborations, Joint Ventures & Partnerships
Table 4.3 Business Expansion and Contracts
Table 4.4 Patent and Approvals
Table 4.5 Mergers and Acquisitions
Table 4.6 Others Developments
Table 4.7 Key Factors Considered for Threat of New Entrants
Table 4.8 Key Factors Affecting Bargaining Power of Buyers
Table 4.9 Key Factors Affecting the Bargaining Power of Suppliers
Table 4.10 Key Factors Affecting Threat of Substitute Products
Table 4.11 Key Factors Determining Rivalry among Existing Firms
Table 5.1 Recent Patents of Some Key Players
Table 5.2 Recent Patents of Some Associations/Organizations
Table 5.3 Other Recent Patents
Table 5.4 Examples of Some Regulatory Bodies/Associations/Consortiums
Table 6.1 Key Development and Trends
Table 6.2 Key Developments and Trends

List of Tables

Table 2.1 Impact of Market Drivers
Table 2.2 Transport Infrastructure: Latin America and the Caribbean Compared with OECD Countries in 2012-2013
Table 2.3 Impact of Market Challenges
Table 3.1 Key Mergers and Acquisitions
Table 3.2 Key Partnerships/Collaborations/Joint Venture/Contracts
Table 3.3 Key Business Expansion Activities
Table 3.4 Key Product Launches
Table 3.5 Key Awards/Achievements/Events
Table 3.6 ITS Associations
Table 4.1 Global ITS for Roadways Market Size, by Application 2015-2022
Table 4.2 Advanced Driver Assistance Systems for Road Safety
Table 4.3 Forms of Road-user Charging
Table 5.1 Global ITS for Roadways Market Size, by Type 2015-2022
Table 7.1 Global ITS for Railways Market Size, by Application 2015-2022
Table 8.1 Global ITS for Airways Market Size, by Application 2015-2022
Table 9.1 Global ITS for Marine Market Size, by Application 2015-2022 1
Table 10.1 North American ITS Market Size, by Country, 2015-2022 1
Table 10.2 ITS Projects in the U.S. 1
Table 10.3 European Intelligent Transport Systems Market Size by County, 2015-2022 1
Table 10.4 ITS Projects in France 1
Table 10.5 Asia Pacific ITS Market Size, by Country, 2015-2022 1
Table 10.6 ITS Market Size in RoW, by Region, 2015-2022 1
 
List of Figures

Figure 1 Vehicle Production & Urbanization
Figure 2 Global ITS Market Snapshot
Figure 3 Global ITS Market for Roadways, by Applications
Figure 4 Global ITS Market for Roadways, by Type
Figure 5 Global ITS Market for Railways, by Application 2017
Figure 6 Global ITS Market for Airways, by Application 2017 & 2022
Figure 7 Global ITS Market for Marine, by Application 2017 & 2022
Figure 8 Global ITS Market, by Geography
Figure 1.1 Global ITS Market Scope
Figure 1.2 Secondary Data Sources
Figure 1.3 Top Down and Bottom up Approach
Figure 1.4 ITS Market Influencing Factors
Figure 1.5 Assumptions and limitations
Figure 2.1 Global Intelligent Transportation Systems Market Dynamics
Figure 2.2 Global Passenger Cars Sales
Figure 2.3 World CO2 Emissions from Fuel Combustion by Sector in 2014
Figure 3.1 Organic & Inorganic Strategies Adopted by the Key Players
Figure 3.2 Share of Key Market Strategies & Developments
Figure 3.3 Total Number of Strategies & Developments
Figure 3.4 Supply Chain Analysis of ITS Industry
Figure 4.1 Global ITS Market Size for Roadways, by Application
Figure 4.2 Intelligent Freight Management Systems
Figure 5.1 Global Intelligent ITS Market Size, by Type
Figure 7.1 Global ITS for Railways Market Size, by Application
Figure 8.1 Global ITS for Airways Market Size, by Application 2015
Figure 9.1 Global ITS for Marine Market Size, by Application 1
Figure 10.1 Global ITS Market Growth Snapshot, by Country 1
Figure 10.2 Global ITS Market Snapshot, by Geography 1
Figure 10.3 North American ITS Market Size by Country 1
Figure 10.4 European ITS Market Size by Country 1
Figure 10.5 Asia-Pacific ITS Market Size, by Country 1
Figure 10.6 ITS Market Size in ROW, by Region 1
Figure 11.1 Geographic Footprint Analysis of Key Players 1
Figure 11.2 Overall Financials 2013-2015 1
Figure 11.3 Geographic Revenue Mix, 2013-2015 1
Figure 11.4 Business Segment Revenue Mix 2013-2015 1
Figure 11.5 Cubic Corporation: SWOT Analysis 1
Figure 11.6 Overall Financials, 2013-2015 1
Figure 11.7 Segment Revenue Mix, 2013-2015 1
Figure 11.8 Automotive Segment Revenue Mix, 2015 1
Figure 11.9 Geographic Revenue Mix, 2015 1
Figure 11.10 Denso Corporation: SWOT Analysis 1
Figure 11.11 Overall Financials 2013-2015 1
Figure 11.12 Geographic Revenue Mix, 2013-2015 1
Figure 11.13 Business Segment Revenue Mix 2013-2015 1
Figure 11.14 Garmin Ltd.: SWOT Analysis 1
Figure 11.15 Overall Financials, 2013-2015 1
Figure 11.16 Segment Revenue Mix, 2013-2015 1
Figure 11.17 Automotive Revenue Mix, 2015 1
Figure 11.18 Geographic Revenue Mix, 2013-2015 1
Figure 11.19 Hitachi Ltd.: SWOT Analysis 1
Figure 11.20 Overall Financials 2014-2017 1
Figure 11.21 Business Segment Revenue Mix 2014-2017 1
Figure 11.22 Geographic Revenue Mix 2014-2017 1
Figure 11.23 Iteris Inc.: SWOT Analysis 1
Figure 11.24 Overall Financials, 2014-2017 1
Figure 11.25 Segment Revenue Mix, 2014-2017 1
Figure 11.26 Geography Revenue Mix, 2014-2017 1
Figure 11.27 Kapsch TrafficCom AG: SWOT Analysis 1
Figure 11.28 Overall Financials 2014-2017 1
Figure 11.29 Business Segment Revenue Mix 2014-2017 1
Figure 11.30 Geographic Revenue Mix 2014-2017 1
Figure 11.31 Nuance Communications: SWOT Analysis 1
Figure 11.32 Overall Financials, 2013-2015 1
Figure 11.33 Geographic Revenue Mix, 2013-2015 1
Figure 11.34 Segment Revenue Mix, 2013-2015 1
Figure 11.35 Q-Free ASA: SWOT Analysis 1
Figure 11.36 Overall Financials, 2014-2017 1
Figure 11.37 Segment Revenue Mix, 2014-2017 1

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories, Inc
  •  LabCorp Of America Holdings
  •  Luminex Corporation
  •  Myriad Genetics Inc
  •  NanoString Technologies Inc
  •  Neo Genomics Inc
  •  Quest Diagnostics Incorporated
  •  Qiagen, Inc
  •  Roche Holding AG-BR
  •  Siemens Healthineers
  •  Thermo Fisher Scientific
  •  Agilent Technologies
  •  Biotheranostics, Inc
  •  Almac group
  •  GeneNews Limited (formerly ChondroGene Limited)
  •  Rosetta Genomics
  •  Epigenomics
  •  Exact Sciences Corporation
  •  Ignyta,Inc
  •  Interpace Diagnostics
  •  Leica Biosystems
  •  BioTime, Inc
  •  Pathway Genomics
  •  Sysmex Corporation
  •  AstraZeneca
  •  Becton Dickinson & Co
  •  Biocept Inc
  •  Cancer Genetics Inc
  •  Danaher Corporation
  •  Foundation Medicine Inc
  •  Illumina Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll